ERYTECH Pharma S.A. Short Interest Down 60.1 percent in May

ERYPDelisted Stock  USD 0.78  0.04  4.88%   
Slightly above 62% of Erytech Pharma's investor base is looking to short. The analysis of current outlook of investing in Erytech Pharma SA suggests that many traders are alarmed regarding Erytech Pharma's prospects. Erytech Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Erytech Pharma SA. Many technical investors use Erytech Pharma SA stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
ERYTECH Pharma S.A. was the target of a significant decrease in short interest in May. As of May 31st, there was short interest totalling 37,900 shares, a decrease of 60.1 percent from the May 15th total of 95,000 shares. Based on an average daily volume of 139,400 shares, the days-to-cover ratio is

Read at thelincolnianonline.com
news
  

Erytech Pharma Fundamental Analysis

We analyze Erytech Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Erytech Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Erytech Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Income

Net Income Comparative Analysis

Erytech Pharma is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Erytech Pharma SA Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Erytech Pharma stock to make a market-neutral strategy. Peer analysis of Erytech Pharma could also be used in its relative valuation, which is a method of valuing Erytech Pharma by comparing valuation metrics with similar companies.

Peers

Erytech Pharma Related Equities

APMAptorum Group   30.77   
0%
100.0%
HCWBHCW Biologics   8.51   
0%
27.0%
UNCYUnicycive Therapeutics   7.25   
0%
23.0%
XRTXXORTX Therapeutics   4.96   
0%
16.0%
SNGXSoligenix   0.90   
2.0%
0%
IKNAIkena Oncology   1.16   
3.0%
0%
GNFTGenfit   3.80   
12.0%
0%
ADXNAddex Therapeutics   4.02   
13.0%
0%
ARMPArmata Pharmaceuticals   4.35   
14.0%
0%
NTRBNutriband   5.21   
16.0%
0%
ELYMEliem Therapeutics   5.88   
19.0%
0%
SRZNSurrozen   6.80   
22.0%
0%
MOLNMolecular Partners   7.22   
23.0%
0%
ATXIAvenue Therapeutics   9.77   
31.0%
0%
XCURExicure   24.38   
79.0%
0%
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in Erytech Stock

If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules